Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis
The DOI matches its Crossref record; 122 of the 127 references it cites were found in a registry or an index.
Abstract
Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands. SPRMs exert clinically relevant tissue-selective progesterone agonist, antagonist, or mixed agonist/antagonist effects on various progesterone target tissues in vivo. Asoprisnil (J867) is the first SPRM to reach an advanced stage of clinical development for the treatment of symptomatic uterine fibroids and endometriosis. Asoprisnil belongs to the class of 11beta-benzaldoxime-substituted estratrienes that exhibit partial progesterone agonist/antagonist effects with high progesterone receptor specificity in animals and humans. Asoprisnil has no antiglucocorticoid activity in humans at therapeutic doses. It exhibits endometrial antiproliferative effects on the endometrium and breast in primates. Unlike progesterone antagonists, asoprisnil does not induce labor in relevant models of pregnancy and parturition. It induces amenorrhea primarily by targeting the endometrium. In human subjects with uterine fibroids, asoprisnil suppressed both the duration and intensity of uterine bleeding in a dose-dependent manner and reduced tumor volume in the absence of estrogen deprivation. In subjects with endometriosis, asoprisnil was effective in reducing nonmenstrual pain and dysmenorrhea. Asoprisnil may, therefore, provide a novel, tissue-selective approach to control endometriosis-related pain. SPRMs have the potential to become a novel treatment of uterine fibroids and endometriosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, a potential good efficacy of SPRMs on endometriosis was suggested [260–262], but no SPRMs are used in clinical practice.”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [260]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Giudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932
High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence
Day Baird, D., Dunson, D. B., Hill, M. C., Cousins, D., & Schectman, J. M. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.99 · Cited by 2,435
Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily
Oñate, S. A., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (1995) · Science · doi:10.1126/science.270.5240.1354 · Cited by 2,387
Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
A transcriptional co-repressor that interacts with nuclear hormone receptors
Chen, J. D., & Evans, R. M. (1995) · Nature · doi:10.1038/377454a0 · Cited by 1,763
Breast cancer and hormone-replacement therapy: the Million Women Study
Beral, V., Banks, E., Reeves, G., & Bull, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14596-5 · Cited by 1,273
Research works printed but not linked: 4
- Giangrande, Recent Prog Horm Res, 54, 291
- Brenner, 2005, Asoprisnil suppresses endometrial proliferation in cynomolgus macaques., J Soc Gynecol Invest, 12, 208A
- Bilyeu, 2002, Interspecies comparison: In vitro metabolism of J867 by hepatocytes and microsomes from male and female human, and various animal species., Drug Metab Rev, 34, 46
- Morris, 2002, Interspecies comparison of the metabolism of J867 following intravenous or oral administration to male and female bile duct-cannulated rats and mice., Drug Metab Rev, 34, 73
Cited by
Bulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
Bulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., Kohlmeier, A., Yin, P., Milad, M., & Wei, J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00242 · Cited by 844
The Management of Uterine Leiomyomas
Vilos, G. A., Allaire, C., Laberge, P.-Y., Leyland, N., Vilos, A. G., Murji, A., & Chen, I. (2015) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30338-8 · Cited by 642
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Lu, N. Z., Wardell, S. E., Burnstein, K. L., Defranco, D., Fuller, P. J., Giguere, V., Hochberg, R. B., McKay, L., Renoir, J.-M., Weigel, N. L., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.9 · Cited by 426
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Dysmenorrhea in Adolescents and Young Adults: Etiology and Management
Harel, Z. (2006) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2006.09.001 · Cited by 297
Role of medical therapy in the management of uterine adenomyosis
Vannuccini, S., Luisi, S., Tosti, C., Sorbi, F., & Petraglia, F. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.013 · Cited by 231
“Similarly, asoprisnil and telapristone acetate have also been reported to relieve endometriosis-associated pain (77).”
BackgroundLaganà, A. S., Vitale, S. G., Salmeri, F. M., Triolo, O., Ban Frangež, H., Vrtačnik-Bokal, E., Stojanovska, L., Apostolopoulos, V., Granese, R., & Sofo, V. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.03.032 · Cited by 221
Non-genomic progesterone actions in female reproduction
Gellersen, B., Fernandes, M. S., & Brosens, J. J. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn044 · Cited by 221
Polymeric Microspheres for Medical Applications
Saralidze, K., Koole, L. H., & Knetsch, M. L. W. (2010) · Materials · doi:10.3390/ma3063537 · Cited by 213
Medical treatment of endometriosis-related pain
Vercellini, P., Buggio, L., Frattaruolo, M. P., Borghi, A., Dridi, D., & Somigliana, E. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.015 · Cited by 188
Segars, J. H., Parrott, E. C., Nagel, J. D., Guo, X. C., Gao, X., Birnbaum, L. S., Pinn, V. W., & Dixon, D. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt058 · Cited by 186
“Progesterone receptor agonists, SPRMs and aromatase inhibitors have been investigated, and targeting of progesterone receptors appears to be an attractive approach for symptomatic fibroid treatment (Chwalisz et al., 2005).”
BackgroundBouchard, P., Chabbert-Buffet, N., & Fauser, B. C. J. M. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.08.021 · Cited by 184
Endometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182
New developments in the medical treatment of endometriosis
Bedaiwy, M. A., Alfaraj, S., Yong, P., & Casper, R. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.025 · Cited by 176
Current medical treatment of uterine fibroids
Sohn, G. S., Cho, S., Kim, Y. M., Cho, C., Kim, M.-R., Lee, S. R., & for the Working Group of Society of Uterine Leiomyoma (2018) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2018.61.2.192 · Cited by 186
Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications
Moravek, M. B., Yin, P., Ono, M., Coon V, J. S., Dyson, M. T., Navarro, A., Marsh, E. E., Chakravarti, D., Kim, J. J., Wei, J.-J., et al. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu048 · Cited by 157
Harel, Z. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.725045 · Cited by 155
“7 Other investigational drugs Another novel approach is the use of a selective progesterone receptor modulator, which has been shown to reduce dysmenorrhea and nonmenstrual pain in patients with endometriosis [100].”
BackgroundWilliams, A. R. W., Bergeron, C., Barlow, D. H., & Ferenczy, A. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318251035b · Cited by 157
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
“In a randomized placebo-controlled trial, this drug (5, 10, and 25 mg) caused a greater reduction of endometriosis-related dysmenorrhea compared with a placebo [104].”
BackgroundMadauss, K. P., Grygielko, E. T., Deng, S.-J., Sulpizio, A. C., Stanley, T. B., Wu, C., Short, S. A., Thompson, S. K., Stewart, E. L., Laping, N. J., et al. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0524 · Cited by 151
Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
“Most SPRMs have been developed for clinical application, and they are a desirable class of drugs due to their tissue selectivity and minimal undesirable side effects (20).”
BackgroundGuo, S.-W. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000096047 · Cited by 144
Chwalisż, K., Larsen, L. M., Mattia‐Goldberg, C., Edmonds, A., Elger, W. A. G., & Winkel, C. A. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.094 · Cited by 138
Self-citationEndometriosis: current and future medical therapies
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Daguati, R., & Crosignani, P. G. (2007) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2007.10.001 · Cited by 152
Williams, A. R. W., Critchley, H. O. D., Osei, J., Ingamells, S., Cameron, I. T., Han, C., & Chwalisz, K. (2007) · Human Reproduction · doi:10.1093/humrep/dem026 · Cited by 122
Contemporary management of uterine fibroids: focus on emerging medical treatments
Singh, S. S., & Belland, L. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.982246 · Cited by 135
Selective progesterone receptor modulators (SPRMs) for uterine fibroids
Murji, A., Whitaker, L. H. R., Chow, T., & Sobel, M. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010770.pub2 · Cited by 134
Endometriosis and Genetic Polymorphisms
Falconer, H., D’Hooghe, T., & Fried, G. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000279293.60436.60 · Cited by 107
Harel, Z. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2661 · Cited by 117
Non-surgical management of uterine fibroids
Tropeano, G., Amoroso, S., & Scambia, G. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn006 · Cited by 111
Wilkens, J., Male, V., Ghazal, P., Forster, T., Gibson, D. A., Williams, A. R. W., Brito-Mutunayagam, S. L., Craigon, M., Lourenco, P., Cameron, I. T., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300958 · Cited by 101
Role of eutopic endometrium in pelvic endometriosis
Carvalho, L., Podgaec, S., Bellodi-Privato, M., Falcone, T., & Abrão, M. S. (2011) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2011.03.009 · Cited by 99
Wilkens, J., Chwalisz, K., Han, C., Walker, J., Cameron, I. T., Ingamells, S., Lawrence, A. C., Lumsden, M. A., Hapangama, D., Williams, A. R. W., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1104 · Cited by 101
Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus
Wetendorf, M., & DeMayo, F. J. (2014) · The International Journal of Developmental Biology · doi:10.1387/ijdb.140069mw · Cited by 116
Yin, P., Lin, Z., Cheng, Y.-H., Marsh, E. E., Utsunomiya, H., Ishikawa, H., Xue, Q., Reierstad, S., Innes, J., Thung, S., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0725 · Cited by 96
Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?
Guo, S.-W., & Groothuis, P. G. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy020 · Cited by 95
Medical Treatments for Endometriosis-Associated Pelvic Pain
Zito, G., Luppi, S., Giolo, E., Martinelli, M., Venturin, I., Di Lorenzo, G., & Ricci, G. (2014) · BioMed Research International · doi:10.1155/2014/191967 · Cited by 93
Harel, Z. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1429.007 · Cited by 127
Progesterone receptor modulators and the endometrium: changes and consequences†
Horne, F. M., & Blithe, D. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm023 · Cited by 98
Chen, W., Ohara, N., Wang, J., Xu, Q., Liu, J., Morikawa, A., Sasaki, H., Yoshida, S., Demanno, D. A., Chwalisz, K., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2379 · Cited by 92
Self-citationYin, P., Lin, Z., Reierstad, S., Wu, J., Ishikawa, H., Marsh, E. E., Innes, J., Cheng, Y., Pearson, K., Coon, J. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2612 · Cited by 89
Yoshida, S., Ohara, N., Xu, Q., Chen, W., Wang, J., Nakabayashi, K., Sasaki, H., Morikawa, A., & Maruo, T. (2010) · Seminars in Reproductive Medicine · doi:10.1055/s-0030-1251483 · Cited by 86
Non-monotonic dose–response relationship in steroid hormone receptor-mediated gene expression
Li, L., Andersen, M. E., Heber, S., & Zhang, Q. (2007) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0003 · Cited by 90
Archer, D. F., Stewart, E. A., Jain, R. I., Feldman, R. A., Lukes, A. S., North, J. D., Soliman, A. M., Gao, J., Ng, J. W., & Chwalisz, K. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.05.006 · Cited by 81
Uterine fibroids: an update on current and emerging medical treatment options
Farris, M., Bastianelli, C., Rosato, E., Brosens, I. A., & Benagiano, G. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s147318 · Cited by 93
Wagenfeld, A., Saunders, P. T. K., Whitaker, L., & Critchley, H. O. D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1180368 · Cited by 79
van Oeveren, A., Motamedi, M., Mani, N. S., Marschke, K. B., LÓPEZ, F. J., Schrader, W. T., Negro-Vilar, A. F., & Zhi, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060792t · Cited by 79
Androgen receptor–cofactor interactions as targets for new drug discovery
Chang, C., & McDonnell, D. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.002 · Cited by 84
Medical treatment for adenomyosis and/or adenomyoma
Tsui, K., Lee, W.-L., Chen, C.-Y., Sheu, B., Yen, M., Chang, T., & Wang, P. (2014) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2014.04.024 · Cited by 89
Evolution of medical treatment for endometriosis: back to the roots?
Wieser, F., Cohen, M., Gaeddert, A., Yu, J., Burks-Wicks, C., Berga, S. L., & Taylor, R. N. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm015 · Cited by 76
Role of Medical Management for Uterine Leiomyomas
Kashani, B. N., Centini, G., Morelli, S. S., Weiss, G., & Petraglia, F. (2015) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2015.11.016 · Cited by 99
Antiprogestins in breast cancer treatment: are we ready?
Lanari, C., Wargon, V., Rojas, P., & Molinolo, A. A. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0378 · Cited by 86
Wu, Y., & Guo, S. (2007) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2007.02.014 · Cited by 79
Progestogens or progestogen-releasing intrauterine systems for uterine fibroids
Sangkomkamhang, U. S., Lumbiganon, P., Laopaiboon, M., & Mol, B. W. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008994.pub2 · Cited by 77
A comprehensive review of hormonal and biological therapies for endometriosis: latest developments
Barra, F., Grandi, G., Tantari, M., Scala, C., Facchinetti, F., & Ferrero, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1581761 · Cited by 69
Wu, Y., & Guo, S.-W. (2006) · Gynecologic and Obstetric Investigation · doi:10.1159/000093975 · Cited by 66
From pathogenesis to clinical practice: Emerging medical treatments for endometriosis
Clemenza, S., Sorbi, F., Noci, I., Capezzuoli, T., Turrini, I., Carriero, C., Buffi, N., Fambrini, M., & Petraglia, F. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.021 · Cited by 63
The Expression and Potential Regulatory Function of MicroRNAs in the Pathogenesis of Leiomyoma
Luo, X., & Chegini, N. (2008) · Seminars in Reproductive Medicine · doi:10.1055/s-0028-1096130 · Cited by 66
Wang, J., Ohara, N., Wang, Z., Chen, W., Morikawa, A., Sasaki, H., DeManno, D. A., Chwalisż, K., & Maruo, T. (2006) · Human Reproduction · doi:10.1093/humrep/del035 · Cited by 68
Self-citationNew trends for the medical treatment of endometriosis
Rocha, A. L. L., Reis, F. M., & Petraglia, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.683783 · Cited by 60
Morikawa, A., Ohara, N., Xu, Q., Nakabayashi, K., DeManno, D. A., Chwalisz, K., Yoshida, S., & Maruo, T. (2008) · Human Reproduction · doi:10.1093/humrep/den025 · Cited by 60
Self-citationChwalisz, K., Surrey, E., & Stanczyk, F. Z. (2012) · Reproductive Sciences · doi:10.1177/1933719112438061 · Cited by 58
The Management of Uterine Leiomyomas
(2003) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30584-9 · Cited by 57
Investigational drugs for the treatment of endometriosis, an update on recent developments
Barra, F., Scala, C., Mais, V., Guerriero, S., & Ferrero, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1471135 · Cited by 57
Zaveri, N. T., & Murphy, B. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00063-8 · Cited by 64
Autophagy in endometriosis: Friend or foe?
Zhan, L., Li, J., & Wei, B. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.145 · Cited by 56
Wu, Y., & Guo, S. (2007) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2006.07.034 · Cited by 61
Byrns, M. C. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.01.015 · Cited by 61
An overview of the current status of clinical trials on endometriosis: issues and concerns
Guo, S. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.08.050 · Cited by 55
Uterine myoma: a condition amendable to medical therapy?
Cheng, M.-H., & Wang, P. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.1.119 · Cited by 54
The evolution of progesterone receptor ligands
Madauss, K. P., Stewart, E. L., & Williams, S. P. (2007) · Medicinal Research Reviews · doi:10.1002/med.20083 · Cited by 53
The immninent dawn of SPRMs in obstetrics and gynecology
Chabbert‐Buffet, N., Pintiaux, A., & Bouchard, P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.02.021 · Cited by 60
Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
Marci, R., Maiorana, A., Carinelli, S. G., Biglia, N., Monte, G. L., & D’Alonzo, M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s54565 · Cited by 64
Geng, R., Huang, X., Li, L., Guo, X., Wang, Q., Zheng, Y., & Guo, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1037504 · Cited by 57
Colón-Caraballo, M., García, M., Mendoza, A., & Flores, I. (2019) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000663 · Cited by 51
Progesterone Receptor Antagonists
Spitz, I. M. (2008) · Methods and Principles in Medicinal Chemistry · doi:10.1002/9783527623297.ch7 · Cited by 50
Luo, X., Yin, P., V., J. S. C., Cheng, Y.-H., Wiehle, R. D., & Bulun, S. E. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.11.031 · Cited by 52
Hypoxia-inducible factor-1alpha: A promising therapeutic target in endometriosis
Zhan, L., Wang, W., Zhang, Y., Song, E., Fan, Y., & Wei, B. (2016) · Biochimie · doi:10.1016/j.biochi.2016.01.006 · Cited by 50
Reproductive tract function and dysfunction in women
Roy, A., & Matzuk, M. M. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.79 · Cited by 54
Ohara, N., Morikawa, A., Chen, W., Wang, J., DeManno, D. A., Chwalisż, K., & Maruo, T. (2007) · Reproductive Sciences · doi:10.1177/1933719107311464 · Cited by 47
Self-citationDysfunctional signaling underlying endometriosis: current state of knowledge
Cho, Y. J., Lee, S. H., Park, J. W., Han, M. S., Park, M. J., & Han, S. J. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0227 · Cited by 54
Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques
Brenner, R. M., Slayden, O. D., Nath, A., Tsong, Y. Y., & Sitruk-Ware, R. (2010) · Contraception · doi:10.1016/j.contraception.2009.11.004 · Cited by 45
Sasaki, H., Ohara, N., Xu, Q., Wang, J., DeManno, D. A., Chwalisż, K., Yoshida, S., & Maruo, T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0898 · Cited by 44
Self-citationLiang, B., Wu, L., Xu, H., Cheung, C. W., Fung, W. Y., Wong, S. W., & Wang, C. C. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0347-9 · Cited by 41
“effects probably due to different effects of SPRMs and progestin [62].”
BackgroundTan, J., Yong, P. J., & Bedaiwy, M. A. (2019) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000555 · Cited by 50
Su, S., Blackwelder, A. J., Grossman, G., Minges, J. T., Yuan, L., Young, S. L., & Wilson, E. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.372797 · Cited by 42
Pandey, V., Tripathi, A., Rani, A., & Dubey, P. K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110751 · Cited by 44
Emerging drugs in endometriosis
Mihalyi, A., Simsa, P., Mutinda, K. C., Meuleman, C., Mwenda, J. M., & D’Hooghe, T. M. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.503 · Cited by 39
Chwalisż, K., Garg, R. C., Brenner, R., Slayden, O. D., Winkel, C. A., & Elger, W. A. G. (2006) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-4-s1-s8 · Cited by 41
Self-citationTen Estrogen-Related Polymorphisms and Endometriosis: A Study of Multiple Gene–Gene Interactions
Huber, A., Keck, C. C., Hefler, L. A., Schneeberger, C., Huber, J. C., Bentz, E.-K., & Tempfer, C. B. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000185259.01648.41 · Cited by 38
A peek into the drug development scenario of endometriosis – A systematic review
Goenka, L., George, M., & Sen, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.092 · Cited by 37
Di, X., Andrews, D. M. K., Tucker, C. J., Yu, L. C., Moore, A. B., Zheng, X., Castro, L., Hermon, T., Xiao, H., & Dixon, D. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.4.024 · Cited by 37
Update on the management of abnormal uterine bleeding
Levy-Zauberman, Y., Pourcelot, A.-G., Capmas, P., & Fernandez, H. (2017) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2017.07.005 · Cited by 44
Cox, J. M., Malik, M., Britten, J., Lewis, T. D., & Catherino, W. H. (2017) · Reproductive Sciences · doi:10.1177/1933719117728802 · Cited by 37
Glace, L. E., Grygielko, E. T., Boyle, R., Wang, Q., Laping, N. J., Sulpizio, A. C., & Bray, J. D. (2009) · Steroids · doi:10.1016/j.steroids.2009.07.011 · Cited by 41
Emerging therapy for endometriosis
Lindsay, S. F., Luciano, D. E., & Luciano, A. A. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051966 · Cited by 45
Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis
Kalampokas, T., Kamath, M. S., Boutas, I., & Kalampokas, E. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1106471 · Cited by 36
Metadata
- Authors
- Chwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W.
- Affiliations
- TAP Pharmaceutical Products, Inc. (K.C., M.C.P., D.D.), Lake Forest, Illinois 60045;
- Georgetown University (US)
- Jenapharm GmbH & Co. (G.S.), 07745 Jena, Germany;
- EnTec GmbH (W.E.), 07745 Jena, Germany
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2005-04-27
- Volume
- 26
- Issue
- 3
- Pages
- 423-438
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W1986914259
- Cited by
- 310
- References
- 127
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 9 · 2019: 16 · 2018: 18 · 2017: 23 · 2016: 11 · 2015: 21 · 2014: 19 · 2013: 21 · 2012: 21
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- selective progesterone receptor modulators, asoprisnil, uterine fibroids, leiomyoma, endometriosis, amenorrhea, dysmenorrhea, drug development
- MeSH terms
- Animals, Clinical Trials as Topic, Endometriosis, Estrenes, Female, Humans, Leiomyoma, Oximes, Oxytocics, Progesterone, Receptors, Progesterone, Uterine Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.